In order to evaluate the role of DUOX2 in chemopotentiation by LDFRT in a pre-clinical model, we first confirmed that LDFRT and the combined regimen resulted in DUOX2 upregulation in human stomach cancer cells. This evidence concerns the gene DUOX2 and gastric neoplasm.